#	Pagina
attuale pagina	/open-h2020/projects/208178/index.html

Opendata, web and dolomites

PANTREAT

Pancreatic cancer as a treatment target of Dwarfbody-Therapeutics

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PANTREAT project word cloud

Explore the words cloud of the PANTREAT project. It provides you a very rough idea of what is the project "PANTREAT" about.

plan molecules 2016 reg attractive off outcome compiled co spin amc supportive reports published deals investments additional business pantreat types primarily aggressive ranked market molecular team obtaining portfolio dwarfbody tx trial sound dwarfbodies administering journals ineffective proof basis amsterdam significantly competing intestinal treatment weight broadening db licencing initial therapeutic 2020 centers onwards transform antibodies grants cancer company anticancer safe form therapeutics gastro cancers frontrunner superiority

Project "PANTREAT" data sheet

The following table provides information about the project.

Coordinator	DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV Organization address address: KWEEKDUINWEG 12 city: OVERVEEN postcode: 2051 EL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://warfbody-therapeutics.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2017
Duration (year-month-day)	from 2017-03-01 to 2017-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV Organization address address: KWEEKDUINWEG 12 city: OVERVEEN postcode: 2051 EL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (OVERVEEN)	coordinator	50˙000.00

Map

Project objective

Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering highly effective and safe low molecular weight antibodies (“Dwarfbodies®”) to significantly increase therapeutic outcome. The superiority of the Dwarfbodies® compared to competing molecules and their anticancer effects have been published in various high ranked journals. Now PANTREAT primarily aims at broadening the initial target market for the Dwarfbodies® by creating additional proof-of-concept, reports on production, test Trial Centers and a sound business plan. Results will be compiled into a sound company portfolio, which will form the basis for further development of the Dwarfbodies® and obtaining investments and supportive grants and partnerships. Finally, this will lead to highly attractive licencing deals from 2020 onwards.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANTREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANTREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers